Nargiz Muganlinskaya

Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study

Introduction Individuals with co-morbid T2D and IBD represent a uniquely high-risk group, facing amplified cardiovascular risk through synergistic inflammatory and metabolic pathways, in whom conventional cardiometabolic strategies (such as dietary and lifestyle changes, weight l...